Strong Revenue Growth
The company reported a 5.4% organic revenue growth in Q4, with notable acceleration in Cardiovascular (8%), Neuromodulation, and Diabetes segments.
Cardiac Ablation Solutions Surge
Cardiac Ablation Solutions grew nearly 30%, driven by high demand for Affera PFA products and the Sphere-9 focal catheter.
Neuromodulation Leads Market
Neuromodulation grew 10%, with a 12% increase in Pain Stim and 15% growth in the US, maintaining the number one global position in SCS.
Diabetes Segment Growth
The Diabetes segment achieved 12% growth, marking the sixth consecutive quarter of double-digit growth, with strong contributions from the MiniMed 780G and Simplera Sync sensor.
Significant Operational Leverage
The company achieved high single-digit operating profit and low double-digit EPS growth, with Q4 EPS growth of 11%.
Portfolio Milestones
Two businesses, CAS and ENT, reached $1 billion in annual revenue, joining ten other businesses in this category.
Separation of Diabetes Business
The decision to separate the Diabetes business into a standalone public company is seen as a strategic move for focused growth and investment.